Mesoblast Ltd. (MESO)
13.39
+0.21
(+1.59%)
USD |
NASDAQ |
Oct 28, 16:00
15.96
+2.57
(+19.19%)
After-Hours: 04:38
Mesoblast Enterprise Value : 1.781B for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | 1.781B |
| October 27, 2026 | 1.754B |
| October 26, 2026 | 1.652B |
| October 23, 2026 | 1.637B |
| October 22, 2026 | 1.672B |
| October 21, 2026 | 1.709B |
| October 20, 2026 | 1.654B |
| October 19, 2026 | 1.595B |
| October 16, 2026 | 1.767B |
| October 15, 2026 | 1.854B |
| October 14, 2026 | 1.833B |
| October 13, 2026 | 1.847B |
| October 12, 2026 | 1.896B |
| October 09, 2026 | 1.898B |
| October 08, 2026 | 1.828B |
| October 07, 2026 | 1.853B |
| October 06, 2026 | 1.810B |
| October 05, 2026 | 1.889B |
| October 02, 2026 | 1.871B |
| October 01, 2026 | 1.902B |
| September 30, 2026 | 1.945B |
| September 29, 2026 | 1.973B |
| September 28, 2026 | 1.925B |
| September 25, 2026 | 2.006B |
| September 24, 2026 | 2.052B |
| Date | Value |
|---|---|
| September 23, 2026 | 2.028B |
| September 22, 2026 | 2.109B |
| September 21, 2026 | 2.052B |
| September 18, 2026 | 2.007B |
| September 17, 2026 | 1.973B |
| September 16, 2026 | 1.914B |
| September 15, 2026 | 1.956B |
| September 14, 2026 | 1.993B |
| September 11, 2026 | 2.052B |
| September 10, 2026 | 2.055B |
| September 09, 2026 | 2.138B |
| September 08, 2026 | 2.170B |
| September 04, 2026 | 2.291B |
| September 03, 2026 | 2.268B |
| September 02, 2026 | 2.287B |
| September 01, 2026 | 2.185B |
| August 31, 2026 | 2.218B |
| August 28, 2026 | 2.307B |
| August 27, 2026 | 2.403B |
| August 26, 2026 | 2.229B |
| August 25, 2026 | 2.274B |
| August 24, 2026 | 2.203B |
| August 21, 2026 | 2.250B |
| August 20, 2026 | 2.305B |
| August 19, 2026 | 2.266B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Telix Pharmaceuticals Ltd. | 3.079B |
| Immutep Ltd. | -- |
| CSL Ltd. | -- |
| Ceryvyn Therapeutics Ltd. | -- |
| Propanc Biopharma, Inc. | 6.663M |
Enterprise Value Related Metrics
| Earnings Yield | -3.33% |
| Normalized Earnings Yield | -3.866 |